PaxMedica Releases Fireside Chat Video with CEO Howard Weisman
PaxMedica unveiled a Fireside Chat video featuring Howard Weisman, Chairman and CEO, providing a detailed company update with insights into recent achievements and advancements.
TARRYTOWN, NY / ACCESSWIRE / December 6, 2023 / PaxMedica, Inc. (NASDAQ:PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, announced the release of a Fireside Chat video featuring Howard Weisman, Chairman and CEO.
In this comprehensive company update video, Mr. Weisman shares insights into PaxMedica's recent achievements and advancements. This presentation underscores the company's commitment to groundbreaking therapies and transformative solutions.
Key Points Covered:
- Regulatory Update: Insights from the recent FDA Type-B meeting on October 25th, shedding light on the regulatory pathway for HAT-PAX-101.
- Financial Boost: A successful $7 million public offering, strengthening PaxMedica's balance sheet and providing a financial platform for production and clinical trial initiatives.
- Strategic Acquisition: Acquiring suramin research assets from Rediscovery Life Sciences (RLS), potentially expediting the NDA submission for PAX-101.
- Clinical Trials Progress: Updates on the Phase 3 trial for HAT-PAX-101 and insights into future Autism Spectrum Disorder (ASD) trials.
- Business Efficiency: PaxMedica's business strategy, emphasizing efficiency, production milestones, and key partnerships with organizations like Vox Nova.
- Future Vision: PaxMedica's business strategy, including NDA plans for PAX-101 and potential advancements in autism treatment.
How to View the Video:
The Fireside Chat video will be available for viewing on www.paxmedica.com simultaneously with this press release.
PaxMedica, Inc. is a forward-looking clinical-stage biopharmaceutical firm specializing in cutting-edge anti-purinergic drug therapies (APT) aimed at addressing a range of challenging neurologic disorders. Our comprehensive portfolio encompasses a spectrum of conditions, including neurodevelopmental disorders such as Autism Spectrum Disorder (ASD), as well as other critical areas within the neurology field. We are dedicated to the continuous development and evaluation of our pioneering program, PAX-101-an intravenous suramin formulation that lies at the heart of our efforts, particularly focused on innovative ASD treatment solutions. Our ongoing research initiatives not only prioritize the needs of ASD patients but also extend to exploring potential therapeutic applications for related conditions. To learn more about our transformative work, please visit www.paxmedica.com.
Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for Email Alerts at https://www.paxmedica.com/email-alerts and by following PaxMedica on Twitter and LinkedIn.
This press release and the video described therein contain "forward-looking statements." Forward-looking statements reflect our current view about future events. Investors can identify these forward-looking statements by words or phrases such as "may," "will," "could," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "is/are likely to," "propose," "potential," "continue" or similar expressions. These forward-looking statements include our anticipated clinical program, the timing and success of our anticipated data announcements, pre-clinical and clinical trials and regulatory filings, statements about the strength of our balance sheet. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company's current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Such risks and uncertainties include, but are not limited to, risks associated with the Company's development work, including any delays or changes to the timing, cost and success of the Company's product development and clinical trials, risk of insufficient capital resources, cash funding and cash burn and risks associated with intellectual property and infringement claims. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results described in the Company's "Risk Factors" section and other sections in its most recent Annual Report on Form 10-K, and subsequent quarterly and other filings with the U.S. Securities and Exchange Commission.